Alpha-fetoprotein (AFP) response in patients with unresectable hepatocellular carcinoma (HCC) in the phase III RESORCE trial

Jordi Bruix; María Reig; Philippe Merle; Masatoshi Kudo; Gudrun Meinhardt; M. Zhang; Kirhan Özgürdal

doi:10.1093/annonc/mdz247.081

Related publications

Article2019

Ramucirumab in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): An exposure-response analysis

Josep M. Llovet, Masatoshi Kudo, Yoon‐Koo Kang, Chia‐Jui Yen, Richard S. Finn, Peter R. Galle, Éric Assenat, Kenta Motomura, Takuji Okusaka, Thomas Berg, Chih‐Hung Hsu, Masafumi Ikeda, Yanzhi Hsu, K. Liang, Ryan C. Widau, William R. Schelman, Lisa M. O’Brien, Ling Gao, Andrew X. Zhu

Annals of Oncology

Article2020

Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): Pooled results from two phase III studies (REACH and REACH-2).

Masatoshi Kudo, Richard S. Finn, Manabu Morimoto, Kun‐Ming Rau, Masafumi Ikeda, Chia‐Jui Yen, Peter R. Galle, Josep M. Llovet, Bruno Daniele, Ho Yeong Lim, Kun Liang, Kenta Shinozaki, Chunxiao Wang, Reigetsu Yoshikawa, Paolo Abada, Ryan C. Widau, Andrew X. Zhu

Journal of Clinical Oncology

Article2019

Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2)

Andrew X. Zhu, Peter R. Galle, Josep M. Llovet, Richard S. Finn, Yoon‐Koo Kang, Chung‐Jen Yen, Éric Assenat, Giovanni Brandi, Kenta Motomura, Izumi Ohno, Bruno Daniele, Arndt Vogel, Tatsuya Yamashita, Chih‐Hung Hsu, Tim Meyer, Ryan C. Widau, William R. Schelman, C. Wang, Yanzhi Hsu, Masatoshi Kudo

Annals of Oncology

Article2019

Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2).

Josep M. Llovet, Chia‐Jui Yen, Richard S. Finn, Yoon‐Koo Kang, Masatoshi Kudo, Peter R. Galle, Éric Assenat, Marc Pracht, Ho Yeong Lim, Kun‐Ming Rau, Christophe Borg, Jean‐Baptiste Hiriart, Bruno Daniele, Thomas Berg, Hyun Cheol Chung, N Godinot, Chunxiao Wang, Yanzhi Hsu, William R. Schelman, Andrew X. Zhu

Journal of Clinical Oncology

Article2020

Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): pooled results from two phase 3 studies (REACH and REACH-2)

Matthias Pinter, Masatoshi Kudo, RS Finn, M Morimot, K.-M. Rau, Masafumi Ikeda, Chia‐Jui Yen, Peter R. Galle, Josep M. Llovet, Bruno Daniele, Howard J. Lim, Khoon Lin Ling, Kazuko Yamaguchi‐Shinozaki, Reigetsu Yoshikawa, C Wang, Paolo Abada, Ryan C. Widau, Andrew X. Zhu

Zeitschrift für Gastroenterologie

Alpha-fetoprotein (AFP) response in patients with unresectable hepatocellular carcinoma (HCC) in the phase III RESORCE trial

Discussion(0)

Related publications

Ramucirumab in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): An exposure-response analysis

Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): Pooled results from two phase III studies (REACH and REACH-2).

Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2)

Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2).

Ramucirumab for patients with intermediate-stage hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): pooled results from two phase 3 studies (REACH and REACH-2)